Skip to content
Screener

Ardelyx ARDX Investing Cash Flow

Investing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$569M-46.3%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$139M-6.9%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$0
AbbVie logo
AbbVieABBV
-$574M+21.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$15.08M
XER
Xeris Biopharma Holdings, Inc.XERS
-$209K+25.1%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$996.75M-23.4%
Enterprise value$1.16B-18.5%
P/S2.2×-1.2×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from maturities and redemptions of investments94,51093,110
Purchases of investments(81,762)(54,361)
Purchases of property and equipment(82)(975)
Net cash provided by investing activities12,66637,774
Financing activities
Proceeds from Loan Agreement, net of costs81,87148,668
Repayment of Loan Agreement, including fees(33,831)
Proceeds from issuance of common stock under equity incentive plans7,1222,470

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's investing cash flow?
Ardelyx (ARDX) reported investing cash flow of $22.66M in Q2 2026.
How has Ardelyx's investing cash flow changed year-over-year?
Ardelyx's investing cash flow decreased by 35.1% year-over-year, from $34.92M to $22.66M.
What is the long-term trend for Ardelyx's investing cash flow?
Over 3 years (2021 to 2024), Ardelyx's investing cash flow has grown at a -28.9% compound annual growth rate (CAGR), from $50.95M to -$18.32M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Ardelyx's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude